Company: DHR
Filing Date: 2025-03-26
Form Type: ARS
Source: 0000313616-25-000085
Chunk: 130

Company: DANAHER CORP /DE/
Filing Date: 2025-03-26
Form: ARS
Chunk 130
---
, 2022 Sales (GAAP) $ 8,758 $ 7,036 $ 10,849 $ — $ 26,643 Less: Depreciation (190) (112) (387) (9) (698) Amortization of intangible assets (812) (419) (203) — (1,434) Other segment expenses(c) (4,748) (5,091) (6,823) (313) (16,975) Operating profit $ 3,008 $ 1,414 $ 3,436 $ (322) $ 7,536 (a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. (b) For information on the impairments, refer to Note 10. (c) Other segment expenses for each reportable segment include cost of sales, selling general and administrative expenses, research and development (“R&D”) expenses, excluding depreciation, amortization of intangible assets and impairments. Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses. 72

The following table presents additional detailed segment data for the years ended December 31 ($ in millions): 2024 2023 2022 Identifiable assets: Biotechnology $ 34,605 $ 37,421 $ 37,536 Life Sciences 23,211 23,730 17,572 Diagnostics 14,204 14,552 14,722 Other 5,522 8,785 9,739 Discontinued operations — — 4,781 Total $ 77,542 $ 84,488 $ 84,350 Capital expenditures, gross: Biotechnology $ 447 $ 417 $ 405 Life Sciences 391 320 325 Diagnostics 550 546 382 Other 4 100 6 Total $ 1,392 $ 1,383 $ 1,118 Operations in Geographical Areas: Year Ended December 31 ($ in millions) 2024 2023 2022 Sales: United States $ 9,927 $ 9,579 $ 11,289 China 2,805 3,143 3,611 All other (each country individually less than 5% of total sales) 11,143 11,168 11,743 Total $ 23,875 $ 23,890 $ 26,643 Property, plant and equipment